São Paulo, August 6, 2024 — Eurofarma, a Brazilian multinational pharmaceutical company with operations in 22 countries and the biggest investor in innovation in Brazil, was selected as the most innovative company in the pharmaceutical and life sciences sector by the Valor Inovação 2024 Awards. The awards ceremony, which is celebrating its 10th anniversary and is one of the most important in Brazil, was held last night, August 5, in São Paulo. 

Eurofarma's vice president of Innovation, Martha Penna, was on the stage to receive the award on behalf of the company’s 12,600 employees, including 750 researchers who work in the company’s innovation laboratory, Eurolab. “This award reflects our spirit of entrepreneurship and innovation that has helped build our history over the past 52 years. We invest in Innovation because we believe our future depends on it. We are proud to be at the forefront of finding solutions that expand access to healthcare and improve people’s quality of life,” she added.

“Our innovation journey also includes efforts aimed at digital transformation, startups, and digital therapies in an integrated healthcare solutions platform. Our goal is to bring truly transformative innovations to the market, to physicians, and to society,” said Rodrigo Pereira, executive director of Entrepreneurship and Digital, who also represented the company at the awards ceremony.

This awards evaluates a company’s innovation journey and the extent its permeates strategies and operations, with investments in research, development, and other vanguardist practices.

Investments

Innovation is part of all the objectives of Eurofarma’s Vision 2027, and this journey has led the company to be the market leader in launches, with 9.2% in the last 24 months. In addition, there are more than 350 projects in the pipeline, of which 30% are radical or incremental, and a total of more than 680 million Brazilian reais has been invested in innovation (data from Eurofarma’s Annual Report 2024, base year 2023).

This work is supported by more than 750 scientists and professionals dedicated to the subject, who count on the facilities of Eurolab, the largest pharmaceutical innovation park, with its structure and ecosystem that is unique in the pharmaceutical industry in Latin America. 

To continue its transformation and move closer to radical innovation, in 2023 the company launched the Eurofarma Ventures corporate fund, which will invest up to 100 million US dollars in biotech companies. The goal is to reach 25 of these companies within five years. The focus is on startups with projects in the early stages of discovery and development of drugs and therapies with disruptive innovations. Most of these companies are in the US market, which is leading this type of initiative.

In the area of Digital Innovation, Eurofarma has made progress in projects focused on health tools for different audiences and new business models. The entire structure is integrated into the EurON innovation platform, which aims to expand activities in the areas of entrepreneurship, open innovation, start-up investments, digital therapies, and strategic data analysis.

To learn more about how Eurofarma works with its pillar of innovation, visit eurofarma.com/annual-report.

About Eurofarma

Established in 1972, Eurofarma operates in the health industry, producing and selling products and services to improve people's quality of life. With a focus on generating shared value, it covers the main pharmaceutical segments, such as prescription, OTC and personal care, generics, hospital, oncology and animal health, as well as providing production services to third parties. With a broad coverage of therapeutic classes, the portfolio comprises more than 2,000 products and 3,700 SKUs (presentations), serving the main medical specialties.

The leader in medical prescriptions in Latin America and in Brazil, where it is second in generics, Eurofarma is present in 22 countries, with 100% coverage in Latin America and operations in the USA and Africa. It has 12,600 employees and 11 factories, with total production of 573 million units in 2023. In the same year, it invested more than R$680 million in innovation and achieved total net revenue of R$9.1 billion. Over the last 15 years, Eurofarma has recorded average annual growth of 17%.

Eurofarma in social media

Facebook: @eurofarma | LinkedIn: @eurofarma

Instagram: @eurofarma | YouTube: @eurofarmalab

Press Information

G&A – Public Relations

Kelly Casarin — +55 (11) 98262-0148 — kelly.casarin@gaspar.com.br

Letícia Remonte — leticia.remonte@gaspar.com.br

Guilherme Gaspar – +55 11 98285-6000 – guilherme@gaspar.com.br